Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 524

1.

Honokiol Is a Potential Therapeutic Agent and Has a Synergistic Effect With 5-FU in Human Urothelial Cell Carcinoma Cells.

Lee MY, Shi CS, Hsu YC, Huang KJ, Chen SH, Zhao PW, Chung HC, Huang YC, Lee YR.

Anticancer Res. 2019 Dec;39(12):6555-6565. doi: 10.21873/anticanres.13871.

PMID:
31810921
2.

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr.

J Clin Oncol. 2019 Nov 4:JCO1902105. doi: 10.1200/JCO.19.02105. [Epub ahead of print]

PMID:
31682550
3.

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn P, He P, McDevitt J, Sheth S, Englert JM, Ku GY.

Clin Cancer Res. 2019 Nov 1. pii: clincanres.2443.2019. doi: 10.1158/1078-0432.CCR-19-2443. [Epub ahead of print]

PMID:
31676670
4.

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer.

Park HS, Kwon WS, Park S, Jo E, Lim SJ, Lee CK, Lee JB, Jung M, Kim HS, Beom SH, Park JY, Kim TS, Chung HC, Rha SY.

J Immunother Cancer. 2019 Oct 21;7(1):268. doi: 10.1186/s40425-019-0708-8.

5.

Regulation of porcine endogenous retrovirus by dual LTR1+2 (Long Terminal Region) miRNA in primary porcine kidney cells.

Chung HC, Nguyen VG, Moon HJ, Park YH, Park BK.

J Vet Sci. 2019 Sep;20(5):e50. doi: 10.4142/jvs.2019.20.e50.

6.

Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.

Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F.

J Cachexia Sarcopenia Muscle. 2019 Aug 28. doi: 10.1002/jcsm.12484. [Epub ahead of print]

7.

Effects of Initial Starting Distance and Gap Characteristics on Children's and Young Adults' Velocity Regulation When Intercepting Moving Gaps.

Chung HC, Choi G, Azam M.

Hum Factors. 2019 Aug 12:18720819867501. doi: 10.1177/0018720819867501. [Epub ahead of print]

PMID:
31403820
8.

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.

Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.

JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243.

9.

Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer.

Kim HS, Koom WS, Baek SE, Kim HI, Jung M, Beom SH, Kang B, Kim H, Chang JS, Choi YY, Son T, Cheong JH, Noh SH, Kim EH, Park JC, Shin SK, Lee SK, Lee YC, Shin SJ, Chung H, Jung I, Chung HC, Lim JS, Hyung WJ, Rha SY.

Radiother Oncol. 2019 Nov;140:143-149. doi: 10.1016/j.radonc.2019.06.029. Epub 2019 Jul 11.

PMID:
31302344
10.

Utilization of a central venous catheter insertion care bundle in Taiwan: A cross-sectional analysis of the National Health Insurance Research Database.

Chung HC, Wang LS, Wu JL, Hsieh TC.

Ci Ji Yi Xue Za Zhi. 2019 Jul-Sep;31(3):182-187. doi: 10.4103/tcmj.tcmj_63_18.

11.

National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database.

Kang HW, Yun SJ, Chung JI, Choi H, Kim JH, Yu HS, Ha YS, Cho IC, Kim HJ, Chung HC, Koh JS, Kim WJ, Park JH, Lee JY, Kim SY.

BMC Health Serv Res. 2019 Jun 24;19(1):408. doi: 10.1186/s12913-019-4218-7.

12.

Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study.

Kim YH, Kim GM, Son S, Song M, Park S, Chung HC, Lee SM.

Support Care Cancer. 2019 Jun 22. doi: 10.1007/s00520-019-04924-9. [Epub ahead of print]

PMID:
31230121
13.

The role of vascular smooth muscle cell membrane-bound thrombomodulin in neointima formation.

Wang KC, Chen PS, Chao TH, Luo CY, Chung HC, Tseng SY, Huang TY, Lin YL, Shi GY, Wu HL, Li YH.

Atherosclerosis. 2019 Aug;287:54-63. doi: 10.1016/j.atherosclerosis.2019.05.019. Epub 2019 May 24.

PMID:
31212235
14.

Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients.

Kwon JH, Lee SC, Lee MA, Kim YJ, Kang JH, Kim JY, Lee HJ, Bae WK, Kim MJ, Chie EK, Kim J, Kim YH, Chung HC, Rha SY.

Cancer Res Treat. 2019 Jul;51(3):851-860. doi: 10.4143/crt.2019.137. Epub 2019 Jun 7.

15.

Controlled Delivery of Stem Cell-Derived Trophic Factors Accelerates Kidney Repair After Renal Ischemia-Reperfusion Injury in Rats.

Yim HE, Kim DS, Chung HC, Shing B, Moon KH, George SK, Kim MW, Atala Z, Kim JH, Ko IK, Yoo JJ.

Stem Cells Transl Med. 2019 Sep;8(9):959-970. doi: 10.1002/sctm.18-0222. Epub 2019 May 30.

16.

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.

Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY.

Gastric Cancer. 2019 Nov;22(6):1153-1163. doi: 10.1007/s10120-019-00971-7. Epub 2019 May 16.

PMID:
31098863
17.

Molecular characterization of a Korean porcine epidemic diarrhea virus strain NB1.

Chung HC, Nguyen VG, Le Huynh TM, Moon HJ, Kang BK, Kim SJ, Kim HK, Park SJ, Park KT, Park YH, Park BK.

Can J Vet Res. 2019 Apr;83(2):97-103.

18.

Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer.

Shin SJ, Park S, Kim MH, Nam CM, Kim H, Choi YY, Jung MK, Choi HJ, Rha SY, Chung HC.

Oncologist. 2019 Nov;24(11):e1108-e1114. doi: 10.1634/theoncologist.2018-0896. Epub 2019 Apr 23.

PMID:
31015316
19.

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.

Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY.

Cancer Res Treat. 2019 Oct;51(4):1578-1588. doi: 10.4143/crt.2018.671. Epub 2019 Apr 16.

20.

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A.

J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.

PMID:
30943124
21.

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC.

Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.

22.

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.

Kim C, Chon HJ, Kim JH, Jung M, Nam CM, Kim HS, Kang B, Chung HC, Rha SY.

Eur J Cancer. 2019 May;112:20-28. doi: 10.1016/j.ejca.2018.11.029. Epub 2019 Mar 19.

PMID:
30901609
23.

Association of baseline histopathology and kidney donor risk index with graft outcomes in deceased donor kidney transplantation
.

Park KS, Park SJ, Park H, Kim M, Park J, Chung HC, Cho HR, Lee JS.

Clin Nephrol. 2019 Jun;91(6):363-369. doi: 10.5414/CN109639.

PMID:
30848240
24.

Spin-polarized magneto-electronic properties in buckled monolayer GaAs.

Chung HC, Chiu CW, Lin MF.

Sci Rep. 2019 Feb 20;9(1):2332. doi: 10.1038/s41598-018-36516-8.

25.

Mode-evolution-based silicon-on-insulator 3  dB coupler using fast quasiadiabatic dynamics.

Hung YJ, Li ZY, Chung HC, Liang FC, Jung MY, Yen TH, Tseng SY.

Opt Lett. 2019 Feb 15;44(4):815-818. doi: 10.1364/OL.44.000815.

PMID:
30767994
26.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.

J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

27.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

28.

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.

Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.

Eur J Cancer. 2019 Feb;108:17-24. doi: 10.1016/j.ejca.2018.11.017. Epub 2018 Dec 25.

PMID:
30592991
29.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.

Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540.

30.

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy.

Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, Kim HI, Cheong JH, Hyung WJ, Choi SH, Jung M, Kim HS, Jeung HC, Chung HC, Rha SY, Noh SH.

BMC Cancer. 2018 Nov 15;18(1):1116. doi: 10.1186/s12885-018-4998-x.

31.

Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.

Kim HM, Jeong I, Kim HJ, Kang SK, Kwon WS, Kim TS, Park KH, Jung M, Soong J, Lin SC, Chung HC, Rha SY.

Anticancer Res. 2018 Nov;38(11):6171-6180. doi: 10.21873/anticanres.12970.

PMID:
30396934
32.

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ.

Future Oncol. 2019 Feb;15(6):567-577. doi: 10.2217/fon-2018-0668. Epub 2018 Oct 31.

33.

A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.

Van Cutsem E, Karaszewska B, Kang YK, Chung HC, Shankaran V, Siena S, Go NF, Yang H, Schupp M, Cunningham D.

Clin Cancer Res. 2019 Apr 15;25(8):2414-2423. doi: 10.1158/1078-0432.CCR-18-1337. Epub 2018 Oct 26.

PMID:
30366938
34.

Experience and Acceptance of Cosmetic Procedures Among South Korean Women in Their 20s.

Seo YA, Chung HC, Kim YA.

Aesthetic Plast Surg. 2019 Apr;43(2):531-538. doi: 10.1007/s00266-018-1257-0. Epub 2018 Oct 25.

35.

Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.

Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, Kim SH, Hur H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim HS.

Oncology. 2019;96(2):59-69. doi: 10.1159/000492597. Epub 2018 Oct 18.

PMID:
30336470
36.

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.

Kim MH, Zhang X, Jung M, Jung I, Park HS, Beom SH, Kim HS, Rha SY, Kim H, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung HC.

Cancer Res Treat. 2019 Apr;51(2):819-831. doi: 10.4143/crt.2018.331. Epub 2018 Sep 27.

37.

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.

Jeong I, Kang SK, Kwon WS, Kim HJ, Kim KH, Kim HM, Lee A, Lee SK, Bogenrieder T, Chung HC, Rha SY.

J Cell Mol Med. 2018 Dec;22(12):5899-5908. doi: 10.1111/jcmm.13859. Epub 2018 Sep 24.

38.

Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer.

Park CH, Kim H, Jo JH, Hahn KY, Yoon JH, Kim SY, Lee YC, Noh SH, Chung HC, Lee SK.

J Gastroenterol Hepatol. 2019 Jan;34(1):84-91. doi: 10.1111/jgh.14471. Epub 2018 Oct 4.

PMID:
30221400
39.

Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.

Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L.

Clin Breast Cancer. 2018 Dec;18(6):489-497. doi: 10.1016/j.clbc.2018.07.024. Epub 2018 Aug 4.

PMID:
30153978
40.

Association between the symptoms of benign prostatic hyperplasia and social disparities: Does social capital promote prostate health?

Park MB, Hyun DS, Song JM, Chung HC, Kwon SW, Kim SC, Ranabhat CL, Lee TS, Koh SB.

Andrologia. 2018 Dec;50(10):e13125. doi: 10.1111/and.13125. Epub 2018 Aug 21.

PMID:
30132961
41.

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.

Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC.

J Glob Oncol. 2018 Jul;4:1-12. doi: 10.1200/JGO.17.00227.

42.

Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecica: A Population-Based Study.

Kim BK, Lee S, Jun M, Chung HC, Oh SS, Lee WS.

Ann Dermatol. 2018 Aug;30(4):402-408. doi: 10.5021/ad.2018.30.4.402. Epub 2018 Jun 27.

43.

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J.

Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

44.

Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.

Park HS, Kim HS, Beom SH, Rha SY, Chung HC, Kim JH, Chun YJ, Lee SW, Choe EA, Heo SJ, Noh SH, Hyung WJ, Cheong JH, Kim HI, Son T, Lim JS, Baek SE, Jung M.

Ann Surg Oncol. 2018 Oct;25(11):3222-3230. doi: 10.1245/s10434-018-6624-1. Epub 2018 Jul 26.

PMID:
30051367
45.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

46.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
47.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

48.
49.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
50.

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy.

Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, Rha SY, Park K.

AAPS J. 2018 May 29;20(4):72. doi: 10.1208/s12248-018-0223-8.

PMID:
29845329

Supplemental Content

Loading ...
Support Center